Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVT-4A1011 for clinically diagnosed insomnia
ACTRN12621001413819Phase 2Recruiting
- Sponsor
- Servatus Biopharmaceuticals
- Start
- Mar 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SVT-4A1011 in Insomnia, sponsored by Servatus Biopharmaceuticals. Primary endpoints: Treatment-emergent adverse events and tolerability, Laboratory safety abnormalities and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
SVT-4A1011
03
Conditions
Insomnia
Beyond the preview
Go deeper on ACTRN12621001413819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001413819.